{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"32.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Decrease from baseline of 1 SDS category (n=32,24)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Decrease from baseline of 2 SDS categories (n=32, 24)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1"},{"groupId":"OG001","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Decrease from baseline of 3 SDS categories(n= 32, 24)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value.","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"},{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis","id":"OG001","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Safety Set (SAF): All patients who received at least one dose of study medication in participants with both a baseline and post-baseline value.","reportingStatus":"POSTED","timeFrame":"from first dosing to 66 cycles","title":"Growth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}